30 September 2025 PayPoint PlcStrategic Investment in Collect+ by International Distribution Services Proposed Special Dividend and associated Share ConsolidationPublication of Circular and Notice of General Meeting PayPoint Plc and International Distribution Services (IDS), owner of Royal Mail, are pleased to announce the next stage in their partnership through a strategic investment in Collect+ to take a 49% ownership, with an investment of £43.9 million, valuing the Collect+ business at £90 million. Cur ...

Core Viewpoint - Morgan Stanley's recent report on Vale (VALE.US) highlights discussions with CFO Marcelo Bacci regarding shareholder returns, railway operations, iron ore product flexibility, copper business growth strategies, and challenges in the nickel segment [1][2]. Group 1: Financial Strategies and Shareholder Returns - The company may distribute a special dividend if net debt falls below $15 billion, with expectations for this to occur by December 2025 if iron ore prices remain high and operations are stable [2][3]. - Management is optimistic about the Brazilian railway concession, despite previous unsuccessful negotiations with the government, and is focused on maintaining control over railway assets until 2057 [2][3]. Group 2: Market Outlook and Product Strategy - The iron ore market is expected to tighten by 2026, with prices projected to remain above $90 per ton, prompting Vale to invest in a flexible product portfolio with an annual capacity of 360 million tons [2][3]. - The company plans to focus on supplying high-silica iron ore to the Chinese market and introducing new mid-grade products, which could generate additional revenue [3]. Group 3: Copper and Nickel Business Developments - The copper business aims to increase production to 700,000 tons per year, primarily relying on internal resources rather than acquisitions, with the Manara project aligning with this growth strategy [3]. - Although the nickel segment has seen cost reductions, it has not yet reached breakeven, and there are no plans for expansion in Canada, with a preference for developing multi-metal mines instead [3].

格隆汇9月10日丨绿心集团(00094.HK)公告，买卖协议于2025年8月29日，卖方(各为公司间接全资附属 公司)与买方订立买卖协议，据此卖方有条件同意出售，而买方有条件同意收购待售资产，代价为1.34 亿新西兰币(相当于6.15亿港元)。建议派发特别股息待股东于股东特别大会上批准及完成后，董事会拟 向于待定记录日期名列公司股东名册之股东派付特别股息每股0.01港元。 公司的主要业务为投资控股。集团的主要业务包括砍伐原木、推销、销售及买卖原木及木材产品以及提 供森林管理服务。各名卖方均为公司间接全资附属公司。卖方一及卖方二分别为投资及林地土地持有公 司，并为待售资产一以及待售资产二之持有公司。卖方三主要从事商业林业投资，并为待售资产三之持 有公司。买方买方为于新西兰注册成立之公司，其主要业务为投资及林业土地持有公司。 应公司要求，股份已自2025年9月1日上午九时正起停止买卖，以待刊发本公告。公司已向联交所提交自 2025年9月11日上午九时正起恢复买卖股份的申请。 买方之最终实益拥有人为一家由Ingvar Kamprad创立的荷兰慈善组织Stichting INGKAFoundation。据董 事经作出 ...

Core Viewpoint - RIMBACO (1953.HK) experienced a significant intraday increase of 107.69%, reaching a new high of 0.27 HKD since December 2022, despite low trading volume of less than 4 million HKD [1] Summary by Relevant Sections - **Stock Performance** - The stock price of RIMBACO surged by 107.69% to 0.27 HKD, marking the highest level since December 2022 [1] - Trading volume remained low, with less than 4 million HKD transacted [1] - **Dividend Announcement** - The company declared a special dividend of 3.7 HKD cents per share [1] - This special dividend is scheduled to be paid on September 15, 2023, to shareholders listed as of the close of business on September 4, 2023 [1]

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has applied for the listing and trading of 112.7 million H-shares on the Hong Kong Stock Exchange, based on the assumption that all shareholders will convert their shares according to the exchange ratio and merger agreement [1][2] Group 1 - The company plans to privatize Dongyang Sunshine Changjiang Pharmaceutical by issuing H-shares as consideration to acquire the H-shares held by shareholders, with a conversion ratio of 0.263614 new H-shares for each H-share of Dongyang Sunshine Changjiang Pharmaceutical [2] - A special dividend of HKD 1.50 per share will be paid to shareholders of Dongyang Sunshine Changjiang Pharmaceutical, who collectively hold approximately 427.6 million shares, upon the completion of the privatization [2] - Upon completion of the privatization, Dongyang Sunshine Changjiang Pharmaceutical's listing status on the exchange will be revoked, and the company will assume all assets, liabilities, and rights of Dongyang Sunshine Changjiang Pharmaceutical [2] Group 2 - The H-shares will be eligible securities for Hong Kong clearing once approved for listing and trading, allowing for deposit, settlement, and transfer in the central clearing system [3]